Clinical Research Directory
Browse clinical research sites, groups, and studies.
GOS and the Management of Hyperuricemia
Sponsor: Sun Yat-sen University
Summary
Hyperuricemia is a major risk factor for many chronic diesease. Recently, gut mcirobiota has been identified as a novel therapeutic target for hyperuricemia. Both annimal studies and pilot human trials have demonstrated that administration of prebiotics help delay the progression of hyperuricemia throuh several mechanisms. This trial aims to examine the protective effects and potential mechanisms of galactooligosaccharide on hyperuricemia in clinical trials.
Official title: The Effectiveness of Galactooligosaccharide on the Treatment of Hyperuricemia
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2024-07-15
Completion Date
2025-12-31
Last Updated
2024-10-08
Healthy Volunteers
Yes
Conditions
Interventions
GOS
During the study period, subjects are instructed to take one pocket of galactooligosaccharide per day during the first week, followed by two pockets of galactooligosaccharide per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
Placebo
During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
Locations (1)
Sun Yat-Sen University
Guangzhou, Guangdong, China